Luteolin Inhibits <scp>NLRP3</scp> Inflammasome Activation to Ameliorate <scp>DSS</scp> ‐Induced Colitis by Regulating <scp>AMPK</scp> Signalling
Lianxiang Luo, Fangfang Huang, Guixuan Fang, Yiming Sun, Liyan Deng, Yinglin Liao, Xinming Chen, Zhuo Chen, Xinxun Lin
Abstract
Luteolin alleviates DSS-induced ulcerative colitis in mice by targeting the NLRP3 inflammasome, as it shows no effect in NLRP3-/- mice. It inhibits NLRP3 activation and IL-1β secretion in macrophages by reducing ROS, mtROS and calcium levels via AMPK binding and signalling. Metabolomic changes suggest lipid metabolism involvement. Luteolin represents a promising NLRP3-targeted therapeutic candidate for UC.
Topics & Concepts
LuteolinInflammasomeAMPKChemistryColitisSecretionUlcerative colitisPharmacologyLipid metabolismSignallingPyrin domainCell biologySignal transductionHedgehog signaling pathwayLipopolysaccharideCancer researchInflammationInflammatory bowel diseaseBiochemistryMetabolismSignalling pathwaysTofacitinibPhosphorylationPeroxisome proliferator-activated receptorKinaseInflammasome and immune disordersIL-33, ST2, and ILC PathwaysImmune cells in cancer